MD Anderson Research Highlights for July 27, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
MD Anderson named #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World...
Cancer cells make unique form of collagen, protecting them...
Cancer cells produce small amounts of their own form of collagen, creating a unique extracellular matrix that affects the tumor...
MD Anderson and Obsidian Therapeutics announce FDA clearance of...
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA)...
Preoperative combination chemotherapy improved survival in...
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery...
Donna Hansel, M.D., Ph.D., to join MD Anderson as Division Head of...
The University of Texas MD Anderson Cancer Center today announced that Donna Hansel, M.D., Ph.D., has been named Division Head of...
MD Anderson Research Highlights for July 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
Kimberly Hoggatt Krumwiede, Ph.D., named Dean of...
The University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School...
Poziotinib is active in EGFR exon 20 mutant non-small cell...
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20...